Drug Trial Radar · NCT07481981
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
344
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Dec 28, 2028
Study completion Jan 28, 2029
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation PowderDrug
Oral inhalation using a capsule-based dry powder inhaler device.
PlaceboDrug
Oral inhalation using a capsule-based dry powder inhaler device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in 6-Minute Walk Distance (6MWD) Measured at 1 to 3 Hours Post-Dose From Baseline at Week 24Time frame: Baseline, Week 24
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
USA012
Los Angeles, California · Recruiting
USA008
Santa Barbara, California · Recruiting
USA005
Torrance, California · Recruiting
USA010
Kansas City, Kansas · Recruiting
USA028
Omaha, Nebraska · Recruiting
USA022
New Hyde Park, New York · Recruiting
USA011
New York, New York · Recruiting
USA015
New York, New York · Recruiting
USA013
Rochester, New York · Recruiting
USA006
Philadelphia, Pennsylvania · Recruiting
USA007
Anderson, South Carolina · Recruiting
ARG001
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
ARG004
Río Cuarto, Córdoba Province, Argentina · Recruiting
ARG005
San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting
AUS002
Camperdown, New South Wales, Australia · Recruiting
AUS003
Westmead, New South Wales, Australia · Recruiting
ISR002
Haifa, Israel · Recruiting
ISR001
Jerusalem, Israel · Recruiting
ISR004
Petah Tikva, Israel · Recruiting
ISR005
Ramat Gan, Israel · Recruiting
ISR003
Tel Aviv, Israel · Recruiting
JPN016
Chiba, Chiba, Japan · Recruiting
JPN011
Narashino, Chiba, Japan · Recruiting
JPN015
Yahatanishi-ku, Kita Kyushu-shi, Fukuoka, Japan · Recruiting
JPN007
Sapporo, Hokkaido, Japan · Recruiting
JPN002
Sapporo, Hokkaido, Japan · Recruiting
JPN014
Kobe, Hyōgo, Japan · Recruiting
JPN003
Okayama, Okayama-ken, Japan · Recruiting
JPN017
Minato-ku, Tokyo, Japan · Recruiting
JPN004
Mitaka-shi, Tokyo, Japan · Recruiting
NZL001
Auckland, New Zealand · Recruiting
NZL003
Dunedin, New Zealand · Recruiting
NZL002
Hamilton, New Zealand · Recruiting
KOR006
Busan, South Korea · Recruiting
KOR003
Incheon, South Korea · Recruiting
KOR002
Seoul, South Korea · Recruiting
KOR005
Seoul, South Korea · Recruiting
KOR001
Seoul, South Korea · Recruiting
TWN002
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.